Security
ProKidney Corp. Class A Ordinary Shares · PROK
PROKNASDAQCommon stockCurrentCIK 1850270Updated Nov 1, 2026
Name history
Social Capital Suvretta Holdings Corp. III · through Jul 11, 2022
PROK price & chart
Loading TradingView…
NASDAQ:PROK on TradingView ↗About the company
ProKidney, a pioneer in the treatment of CKD through innovations in cell therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, rilparencel (also known as REACT®), is a first-in-class, patented, proprietary autologous cell therapy with regenerative medicine advanced therapy designation that is being evaluated in the ongoing Phase 3 REGEN-006 (PROACT 1) study for its potential to preserve kidney function in patients with advanced CKD and type 2 diabetes. For more information, please visit www.prokidney.com.
In the news
ProKidney Reports First Quarter 2026 Financial Results and Business Highlights ↗
Seeking Alpha
ProKidney Corp. (PROK) Discusses Rilparencel Mechanism and Role in Advanced Chronic Kidney Disease - Slideshow ↗
ProKidney Corp. (PROK) Discusses Rilparencel Mechanism and Role in Advanced Chronic Kidney Disease Transcript ↗
ProKidney: Do-Or-Die Phase 3 Meets A Dwindling Balance Sheet (Rating Downgrade) ↗
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 351,608,000Source | 474,793,000Source | 249,016,000Source | 372,133,000Source | 499,163,000Source | 292,784,000Source | 406,061,000Source | 387,763,000Source | 335,574,000Source | 441,073,000Source | 420,552,000Source | 517,996,000Source |
| Property, Plant and Equipment, NetUSD | 47,754,000Source | 38,519,000Source | 56,037,000Source | 43,525,000Source | 42,567,000Source | 54,441,000Source | 43,326,000Source | 41,937,000Source | 51,231,000Source | 42,222,000Source | 42,143,000Source | 10,708,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 95,323,000Source | 108,088,000Source | 74,868,000Source | 84,940,000Source | 214,508,000Source | 101,895,000Source | 97,805,000Source | 84,389,000Source | 108,537,000Source | 99,120,000Source | 60,649,000Source | 490,252,000Source |
| Assets, CurrentUSD | 299,989,000Source | 430,225,000Source | 189,768,000Source | 324,440,000Source | 450,262,000Source | 234,902,000Source | 359,662,000Source | 340,158,000Source | 280,679,000Source | 395,884,000Source | 374,146,000Source | 504,719,000Source |
| Operating Lease, Right-of-Use AssetUSD | 3,803,000Source | 5,939,000Source | 3,146,000Source | 4,095,000Source | 6,212,000Source | 3,372,000Source | 2,988,000Source | 5,534,000Source | 3,590,000Source | 2,869,000Source | 4,116,000Source | 2,285,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 33,270,000Source | 31,325,000Source | 26,178,000Source | 32,680,000Source | 26,797,000Source | 29,680,000Source | 36,084,000Source | 24,728,000Source | 34,781,000Source | 39,436,000Source | 29,216,000Source | 13,057,000Source |
| Stockholders’ equity: | ||||||||||||
| Additional Paid in CapitalUSD | 242,480,000Source | 199,509,000Source | 434,765,000Source | 231,576,000Source | 189,267,000Source | 266,112,000Source | 218,926,000Source | 53,114,000Source | 258,552,000Source | 205,736,000Source | 36,114,000Source | 7,476,000Source |
| Retained Earnings (Accumulated Deficit)USD | -1,250,604,000Source | -1,179,571,000Source | -1,318,294,000Source | -1,234,135,000Source | -1,161,661,000Source | -1,289,872,000Source | -1,217,583,000Source | -1,149,155,000Source | -1,269,835,000Source | -1,200,849,000Source | -1,139,663,000Source | -1,104,116,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 74,000Source | 321,000Source | -34,000Source | 30,000Source | -6,000Source | -53,000Source | 75,000Source | -44,000Source | 56,000Source | 130,000Source | 130,000Source | — |
| Stockholders' Equity Attributable to ParentUSD | -1,008,020,000Source | -979,712,000Source | -883,532,000Source | -1,002,500,000Source | -972,371,000Source | -1,023,783,000Source | -998,553,000Source | -1,096,062,000Source | -1,011,197,000Source | -994,954,000Source | -1,103,396,000Source | -1,096,616,000Source |
| Liabilities and EquityUSD | 351,608,000Source | 474,793,000Source | 249,016,000Source | 372,133,000Source | 499,163,000Source | 292,784,000Source | 406,061,000Source | 387,763,000Source | 335,574,000Source | 441,073,000Source | 420,552,000Source | 517,996,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 29,063,000Source | 25,181,000Source | 22,710,000Source | 28,262,000Source | 20,589,000Source | 25,931,000Source | 32,808,000Source | 19,301,000Source | 30,742,000Source | 36,217,000Source | 25,038,000Source | 10,873,000Source |
| Operating Lease, Liability, CurrentUSD | 973,000Source | 1,032,000Source | 1,112,000Source | 896,000Source | 988,000Source | 1,091,000Source | 840,000Source | 1,039,000Source | 1,054,000Source | 740,000Source | 751,000Source | 458,000Source |
| Accounts Payable, CurrentUSD | 1,942,000Source | 2,850,000Source | 1,610,000Source | 2,443,000Source | 2,933,000Source | 2,592,000Source | 3,122,000Source | 3,376,000Source | 940,000Source | 3,633,000Source | 5,098,000Source | 3,044,000Source |
| Operating Lease, Liability, NoncurrentUSD | 3,181,000Source | 5,290,000Source | 2,344,000Source | 3,446,000Source | 5,554,000Source | 2,620,000Source | 2,439,000Source | 4,769,000Source | 2,905,000Source | 2,393,000Source | 3,506,000Source | 1,858,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 26,068,000Source | 21,264,000Source | 19,971,000Source | 24,916,000Source | 15,109,000Source | 22,231,000Source | 27,572,000Source | 13,263,000Source | 28,731,000Source | 31,137,000Source | 17,665,000Source | 7,336,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | -35,843,000Source | -41,053,000Source | -46,436,000Source | -36,965,000Source | -42,621,000Source | -37,952,000Source | -151,612,000Source | -163,335,000Source | -135,447,000Source | -148,135,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 1,658,000Source | 1,600,000Source | 6,575,000Source | 5,432,000Source | 3,853,000Source | 3,036,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 4,945,000Source | 6,416,000Source | 25,336,000Source | 29,372,000Source | 30,846,000Source | 74,469,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -41,684,000Source | -29,592,000Source | -120,117,000Source | -126,351,000Source | -90,069,000Source | -77,089,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 34,827,000Source | 28,289,000Source | 103,965,000Source | 20,414,000Source | -329,983,000Source | -1,738,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 3,785,000Source | 1,135,000Source | 15,196,000Source | 29,509,000Source | 34,197,000Source | 1,846,000Source |
| Cash flows from financing activities: | ||||||||||||
| Payments for Repurchase of Common StockUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | 9,499,000Source | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 215,000Source | -12,000Source | 25,569,000Source | 144,408,000Source | -9,551,000Source | 548,521,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -6,642,000Source | -1,315,000Source | 9,417,000Source | 38,471,000Source | -429,603,000Source | 469,694,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 95,323,000Source | 108,088,000Source | 74,868,000Source | 84,940,000Source | 101,895,000Source | 97,805,000Source | 108,537,000Source | 99,120,000Source | 60,649,000Source | 490,252,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 2,442,000Source | 73,000Source | 2,857,000Source | 1,950,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 6,675,000Source | 6,934,000Source | 5,594,000Source | 6,540,000Source | 4,944,000Source | 6,416,000Source | 25,336,000Source | 29,372,000Source | 30,846,000Source | 74,469,000Source |
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | — | — | 0Source | — | 213,000Source | 215,000,000Source |
| DepreciationUSD | — | — | 1,398,000Source | 1,199,000Source | 1,449,000Source | 1,491,000Source | 1,435,000Source | 1,384,000Source | 5,722,000Source | 4,337,000Source | 2,956,000Source | 2,448,000Source |
| Gain (Loss) on InvestmentsUSD | — | — | — | — | — | — | 413,000Source | 1,069,000Source | 3,417,000Source | 6,995,000Source | — | — |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | 0Source | -300,000Source | -1,431,000Source | -56,000Source | -23,000Source | — |
| Gain (Loss) on Termination of LeaseUSD | — | — | — | — | — | — | — | — | 29,000Source | 161,000Source | — | — |
| General and Administrative ExpenseUSD | — | — | 11,935,000Source | 17,723,000Source | 12,428,000Source | 14,048,000Source | 11,317,000Source | 14,355,000Source | 51,777,000Source | 56,084,000Source | 44,815,000Source | 70,937,000Source |
| Income Tax Expense (Benefit)USD | — | — | 560,000Source | -2,342,000Source | 0Source | 848,000Source | 0Source | 591,000Source | 414,000Source | -598,000Source | 5,996,000Source | 896,000Source |
| Marketable Securities, Unrealized Gain (Loss)USD | — | — | 44,000Source | 327,000Source | 19,000Source | -45,000Source | -109,000Source | -55,000Source | -74,000Source | — | 130,000Source | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -16,469,000Source | -17,910,000Source | -28,422,000Source | -16,552,000Source | -20,037,000Source | -16,734,000Source | -68,986,000Source | -61,186,000Source | -35,468,000Source | — |
| Operating ExpensesUSD | — | — | 38,756,000Source | 48,973,000Source | 48,523,000Source | 39,930,000Source | 45,159,000Source | 41,618,000Source | 165,900,000Source | 183,752,000Source | 151,522,000Source | 153,007,000Source |
| Operating Lease, ExpenseUSD | — | — | 339,000Source | 479,000Source | 319,000Source | 298,000Source | 355,000Source | 321,000Source | 1,255,000Source | 1,976,000Source | 1,062,000Source | 551,000Source |
| Proceeds from Contributed CapitalUSD | — | — | — | — | — | — | — | — | — | — | — | 6,050,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | 7,000Source | — | 24,247,000Source | 144,322,000Source | 0Source | 542,503,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 211,000Source | 0Source | 1,348,000Source | 140,000Source | — | — |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | 217,000Source | 0Source | 150,000Source | 221,000Source | 226,000Source | 230,000Source | 893,000Source | 76,000Source | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -38,539,000Source | -48,973,000Source | -48,373,000Source | -39,709,000Source | -44,933,000Source | -41,388,000Source | -165,007,000Source | -183,676,000Source | -151,522,000Source | -153,007,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -35,283,000Source | -43,395,000Source | -46,436,000Source | -36,117,000Source | -42,621,000Source | -37,361,000Source | -151,198,000Source | -163,933,000Source | -129,451,000Source | -147,239,000Source |
| Income Tax Expense (Benefit)USD | — | — | 560,000Source | -2,342,000Source | 0Source | 848,000Source | 0Source | 591,000Source | 414,000Source | -598,000Source | 5,996,000Source | 896,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -16,469,000Source | -17,910,000Source | -28,422,000Source | -16,552,000Source | -20,037,000Source | -16,734,000Source | -68,986,000Source | -61,186,000Source | -35,468,000Source | — |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | — | — | 0Source | — | 213,000Source | 215,000Source |
| Gain (Loss) on InvestmentsUSD | — | — | — | — | — | — | 413,000Source | 1,069,000Source | 3,417,000Source | 6,995,000Source | — | — |
| General and Administrative ExpenseUSD | — | — | 11,935,000Source | 17,723,000Source | 12,428,000Source | 14,048,000Source | 11,317,000Source | 14,355,000Source | 51,777,000Source | 56,084,000Source | 44,815,000Source | 70,937,000Source |
| Interest ExpenseUSD | — | — | 2,000Source | 2,000Source | 1,000Source | 1,000Source | 15,000Source | 0Source | 4,000Source | 9,000Source | 12,000Source | -215,000Source |
| Noncontrolling Interest in Net Income (Loss) Other Noncontrolling Interests, RedeemableUSD | — | — | -19,374,000Source | -23,143,000Source | -18,014,000Source | -20,413,000Source | -22,584,000Source | -21,218,000Source | -82,626,000Source | -102,149,000Source | -99,979,000Source | — |
| Operating ExpensesUSD | — | — | 38,756,000Source | 48,973,000Source | 48,523,000Source | 39,930,000Source | 45,159,000Source | 41,618,000Source | 165,900,000Source | 183,752,000Source | 151,522,000Source | 153,007,000Source |
| Operating Lease, ExpenseUSD | — | — | 339,000Source | 479,000Source | 319,000Source | 298,000Source | 355,000Source | 321,000Source | 1,255,000Source | 1,976,000Source | 1,062,000Source | 551,000Source |
| Research and Development ExpenseUSD | — | — | 26,821,000Source | 31,250,000Source | 36,095,000Source | 25,882,000Source | 33,842,000Source | 27,263,000Source | 114,123,000Source | 127,668,000Source | 106,707,000Source | 82,070,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | 217,000Source | 0Source | 150,000Source | 221,000Source | 226,000Source | 230,000Source | 893,000Source | 76,000Source | — | — |
Offerings
Registration 333-299700
Registration 333-286278
Filing attachments
d81716dex43.htm · S-3 · 2026-10-29
Exhibit 4.3 PROKIDNEY CORP. Issuer AND [ ] Trustee INDENTURE Dated as of [ ] Senior Debt Securities TABLE OF CONTENTS 1 Page ARTICLE I DEFINITIONS …
Read attachment ↗d81716dex44.htm · S-3 · 2026-10-29
Exhibit 4.4 PROKIDNEY CORP. Issuer AND [ ] Trustee INDENTURE Dated as of [ ] Subordinated Debt Securities TABLE OF CONTENTS 1 Page ARTICLE I DEFINITIONS 1 SECTION 1.01 …
Read attachment ↗prok-ex99_1.htm · 8-K · 2026-08-10
EX-99.1 2 prok-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 ProKidney Reports Second Quarter 2026 Financial Results and Business Highlights • Completed enrollment of patients contributing to the Phase 3 PROACT 1 accelerated approval efficacy analysis, positioning the Company for anticipated pivotal eGFR slope topline results in Q2 2027 • On track for completion of full enrollment for PROACT 1 in the second half of 2026 • Appointed Kenneth Locke as Chief Technical Officer, adding more than 25…
Read attachment ↗prok-ex99_1.htm · 8-K · 2026-05-15
EX-99.1 2 prok-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 ProKidney Reports First Quarter 2026 Financial Results and Business Highlights • On track to complete enrollment for the Phase 3 PROACT 1 accelerated approval analysis of rilparencel in mid-2026; anticipate pivotal topline results in Q2 2027 • Peer-reviewed results from the Phase 2 REGEN-007 study were published in the Clinical Journal of the American Society of Nephrology (CJASN) in January 2026 • Ended Q1 2026 with $224.9 million …
Read attachment ↗prok-ex99_2.htm · 8-K · 2026-05-15
EX-99.2 3 prok-ex99_2.htm EX-99.2 Transforming the Future of Chronic Kidney Disease Treatment Corporate Presentation May 2026 Preserving Kidney Function in Patients at High Risk of Kidney Failure Exhibit 99.2 This presentation includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. ProKidney’s actual results may differ from its expectations, estimates and projections and consequently, you should not r…
Read attachment ↗ef20071728_ex99-1.htm · 4 · 2026-04-30
Exhibit 99.1 Name and Address of Additional Reporting Persons: Mr. Carlos Slim Helú, Mr. Carlos Slim Domit, Mr. Marco Antonio Slim Domit, Mr. Patrick Slim Domit, Ms. María Soumaya Slim Domit, Ms. Vanessa Paola Slim Domit and Ms. Johanna Monique Slim Domit (collectively, the “Slim Family”), each with the following address: Paseo de Las Palmas #736 Colonia Lomas de Chapultepec 11000 Ciudad de México, México Explanation of Responses: Beneficial Ownership As of the date of this filing, (i) C…
Read attachment ↗